China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
93 hedge funds and large institutions have $1.45B invested in China Biologic Products Holdings, Inc. in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 42 increasing their positions, 21 reducing their positions, and 20 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 21
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
1% less funds holding
Funds holding: 94 → 93 (-1)
14% less capital invested
Capital invested by funds: $1.69B → $1.45B (-$238M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
94% less call options, than puts
Call options by funds: $388K | Put options by funds: $6.11M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
+$79.2M |
| 2 |
HSBC Holdings
London,
United Kingdom
|
+$49.2M |
| 3 |
Goldman Sachs
New York
|
+$44.5M |
| 4 |
BCIM
Black Creek Investment Management
Toronto,
Ontario, Canada
|
+$33M |
| 5 |
ICP
Indus Capital Partners
New York
|
+$27.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$74.8M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$68.7M |
| 3 |
HIM
Hermes Investment Management
London Uk,
United Kingdom
|
-$65.7M |
| 4 |
CCMH
Cornerstone Capital Management Holdings
New York
|
-$33.5M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$23.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NEI
101
Northwest & Ethical Investments
Toronto,
Ontario, Canada
| – | -$692K | -7,501 | Closed |
|
102
Balyasny Asset Management
Chicago,
Illinois
| – | -$655K | -7,100 | Closed |
|
103
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
| – | -$439K | -4,763 | Closed |
|
|
VF
104
Virtu Financial
New York
| – | -$265K | -2,870 | Closed |
|
|
GCA
105
Gideon Capital Advisors
New York
| – | -$230K | -2,494 | Closed |
|
106
Simplex Trading
Chicago,
Illinois
| – | -$148K | -1,781 | Closed |
|
|
PCM
107
Prelude Capital Management
New York
| – | -$46K | -500 | Closed |
|
|
NIT
108
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
| – | -$27K | -295 | Closed |
|
|
CG
109
Cutler Group
San Francisco,
California
| – | -$18K | -200 | Closed |
|
110
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -6 | Closed |
|
|
FGC
111
Financial Gravity Companies
Lakeway,
Texas
| – | +$83 | +1 | New |
|
|
WAP
112
Wealthcare Advisory Partners
West Chester,
Pennsylvania
| – | +$416 | +5 | New |
|
CBPO Hedge Fund Activity: Q4 2017 in Review
93 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q4 2017, worth a combined $1.45B — down 14% from $1.69B a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of CBPO and 19 opened new positions — a net loss of 1 holder — while 21 trimmed existing stakes and 42 added.
The largest buyer was Temasek Holdings, adding an estimated $79.2M. The largest seller was Fidelity Investments, cutting an estimated $74.8M.
- 93 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q4 2017, down from 94 in Q3 2017.
- Funds reported $1.45B of China Biologic Products Holdings, Inc. stock for Q4 2017, down 14% quarter-over-quarter.
- 19 funds opened new China Biologic Products Holdings, Inc. positions in Q4 2017 and 20 closed out, a net change of -1 holder.
- The largest China Biologic Products Holdings, Inc. buyer in Q4 2017 was Temasek Holdings, an estimated $79.2M added.
- The largest China Biologic Products Holdings, Inc. seller in Q4 2017 was Fidelity Investments, an estimated $74.8M sold.
Based on aggregated 13F filings for Q4 2017.